Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies
about
Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin - activity against ovarian cancer cells.A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations.Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and TanzaniaThe efficacy of trabectedin in treating ovarian cancer.
P2860
Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Effect of trabectedin on the Q ...... anced solid tumor malignancies
@ast
Effect of trabectedin on the Q ...... anced solid tumor malignancies
@en
type
label
Effect of trabectedin on the Q ...... anced solid tumor malignancies
@ast
Effect of trabectedin on the Q ...... anced solid tumor malignancies
@en
prefLabel
Effect of trabectedin on the Q ...... anced solid tumor malignancies
@ast
Effect of trabectedin on the Q ...... anced solid tumor malignancies
@en
P2093
P2860
P1476
Effect of trabectedin on the Q ...... anced solid tumor malignancies
@en
P2093
A P Staddon
G M Manikhas
J B Vermorken
J Natarajan
P Zannikos
R Thertulien
P2860
P2888
P304
P356
10.1007/S00280-011-1697-6
P577
2011-07-08T00:00:00Z